▶ 調査レポート

家族性アミロイド多発神経障害の世界市場 2020年：企業別、地域別、種類・用途別
• 英文タイトル：Global Familial Amyloid Polyneuropathy Market 2020 by Company, Regions, Type and Application, Forecast to 2025

GlobalInfoResearchが調査・発行した産業分析レポートです。家族性アミロイド多発神経障害の世界市場 2020年：企業別、地域別、種類・用途別 / Global Familial Amyloid Polyneuropathy Market 2020 by Company, Regions, Type and Application, Forecast to 2025 / D005-00397資料のイメージです。• レポートコード：D005-00397
• 出版社/出版日：GlobalInfoResearch / 2020年5月29日
※2024年版があります。お問い合わせください。
• レポート形態：英文、PDF、107ページ
• 納品方法：Eメール
• 産業分類：医療・製薬
• 販売価格（消費税別）
  Single User￥522,000 (USD3,480)▷ お問い合わせ
  Multi User￥783,000 (USD5,220)▷ お問い合わせ
  Corporate User￥1,044,000 (USD6,960)▷ お問い合わせ
• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
本調査レポートでは、家族性アミロイド多発神経障害の世界市場を広く調査・分析し、今後の市場展望をまとめております。家族性アミロイド多発神経障害の種類別市場規模（FAP-I、FAP-II、FAP-III、FAP-IV）、用途別市場規模（病院・診療所、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。
・市場概要
・企業情報（販売量、市場シェア、製品概要、SWOT分析）：Pfizer、Alnylam、GSK、Arcturus Therapeutics、Ionis、Proclara Bioscience、Corino Therapeutics
・地域別グローバル市場分析 2015年-2020年
・家族性アミロイド多発神経障害の北米市場（アメリカ、カナダ、メキシコ）
・家族性アミロイド多発神経障害のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア）
・家族性アミロイド多発神経障害のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア）
・家族性アミロイド多発神経障害の南米市場（ブラジル、アルゼンチン）
・家族性アミロイド多発神経障害の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ）
・種類別分析：FAP-I、FAP-II、FAP-III、FAP-IV
・用途別分析：病院・診療所、その他
・地域別市場規模予測 2021年-2025年
・販売チャネル、流通業者、代理店
・調査の結果・結論

Market Overview
The global Familial Amyloid Polyneuropathy market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.

The Familial Amyloid Polyneuropathy market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Market segmentation
Familial Amyloid Polyneuropathy market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

By Type, Familial Amyloid Polyneuropathy market has been segmented into:
FAP-I
FAP-II
FAP-III
FAP-IV

By Application, Familial Amyloid Polyneuropathy has been segmented into:
Hospitals and Clinics
Others

Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Familial Amyloid Polyneuropathy market presented in the report. This section sheds light on the sales growth of different regional and country-level Familial Amyloid Polyneuropathy markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Familial Amyloid Polyneuropathy market.

The report offers in-depth assessment of the growth and other aspects of the Familial Amyloid Polyneuropathy market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Competitive Landscape and Familial Amyloid Polyneuropathy Market Share Analysis
Familial Amyloid Polyneuropathy competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Familial Amyloid Polyneuropathy sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Familial Amyloid Polyneuropathy sales, revenue and market share for each player covered in this report.

The major players covered in Familial Amyloid Polyneuropathy are:
Pfizer
Alnylam
GSK
Arcturus Therapeutics
Ionis
Proclara Bioscience
Corino Therapeutics

レポート目次

Table of Contents

1 Familial Amyloid Polyneuropathy Market Overview
1.1 Product Overview and Scope of Familial Amyloid Polyneuropathy
1.2 Classification of Familial Amyloid Polyneuropathy by Type
1.2.1 Global Familial Amyloid Polyneuropathy Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Familial Amyloid Polyneuropathy Revenue Market Share by Type in 2019
1.2.3 FAP-I
1.2.4 FAP-II
1.2.5 FAP-III
1.2.6 FAP-IV
1.3 Global Familial Amyloid Polyneuropathy Market by Application
1.3.1 Overview: Global Familial Amyloid Polyneuropathy Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospitals and Clinics
1.3.3 Others
1.4 Global Familial Amyloid Polyneuropathy Market by Regions
1.4.1 Global Familial Amyloid Polyneuropathy Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Familial Amyloid Polyneuropathy (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Familial Amyloid Polyneuropathy Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Familial Amyloid Polyneuropathy Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Familial Amyloid Polyneuropathy Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Familial Amyloid Polyneuropathy Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Familial Amyloid Polyneuropathy Status and Prospect (2015-2025)
2 Company Profiles
2.1 Pfizer
2.1.1 Pfizer Details
2.1.2 Pfizer Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Pfizer SWOT Analysis
2.1.4 Pfizer Product and Services
2.1.5 Pfizer Familial Amyloid Polyneuropathy Revenue, Gross Margin and Market Share (2018-2019)
2.2 Alnylam
2.2.1 Alnylam Details
2.2.2 Alnylam Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Alnylam SWOT Analysis
2.2.4 Alnylam Product and Services
2.2.5 Alnylam Familial Amyloid Polyneuropathy Revenue, Gross Margin and Market Share (2018-2019)
2.3 GSK
2.3.1 GSK Details
2.3.2 GSK Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 GSK SWOT Analysis
2.3.4 GSK Product and Services
2.3.5 GSK Familial Amyloid Polyneuropathy Revenue, Gross Margin and Market Share (2018-2019)
2.4 Arcturus Therapeutics
2.4.1 Arcturus Therapeutics Details
2.4.2 Arcturus Therapeutics Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Arcturus Therapeutics SWOT Analysis
2.4.4 Arcturus Therapeutics Product and Services
2.4.5 Arcturus Therapeutics Familial Amyloid Polyneuropathy Revenue, Gross Margin and Market Share (2018-2019)
2.5 Ionis
2.5.1 Ionis Details
2.5.2 Ionis Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Ionis SWOT Analysis
2.5.4 Ionis Product and Services
2.5.5 Ionis Familial Amyloid Polyneuropathy Revenue, Gross Margin and Market Share (2018-2019)
2.6 Proclara Bioscience
2.6.1 Proclara Bioscience Details
2.6.2 Proclara Bioscience Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Proclara Bioscience SWOT Analysis
2.6.4 Proclara Bioscience Product and Services
2.6.5 Proclara Bioscience Familial Amyloid Polyneuropathy Revenue, Gross Margin and Market Share (2018-2019)
2.7 Corino Therapeutics
2.7.1 Corino Therapeutics Details
2.7.2 Corino Therapeutics Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Corino Therapeutics SWOT Analysis
2.7.4 Corino Therapeutics Product and Services
2.7.5 Corino Therapeutics Familial Amyloid Polyneuropathy Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Familial Amyloid Polyneuropathy Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Familial Amyloid Polyneuropathy Players Market Share
3.2.2 Top 10 Familial Amyloid Polyneuropathy Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Familial Amyloid Polyneuropathy Revenue and Market Share by Regions
4.2 North America Familial Amyloid Polyneuropathy Revenue and Growth Rate (2015-2020)
4.3 Europe Familial Amyloid Polyneuropathy Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Familial Amyloid Polyneuropathy Revenue and Growth Rate (2015-2020)
4.5 South America Familial Amyloid Polyneuropathy Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Familial Amyloid Polyneuropathy Revenue and Growth Rate (2015-2020)
5 North America Familial Amyloid Polyneuropathy Revenue by Countries
5.1 North America Familial Amyloid Polyneuropathy Revenue by Countries (2015-2020)
5.2 USA Familial Amyloid Polyneuropathy Revenue and Growth Rate (2015-2020)
5.3 Canada Familial Amyloid Polyneuropathy Revenue and Growth Rate (2015-2020)
5.4 Mexico Familial Amyloid Polyneuropathy Revenue and Growth Rate (2015-2020)
6 Europe Familial Amyloid Polyneuropathy Revenue by Countries
6.1 Europe Familial Amyloid Polyneuropathy Revenue by Countries (2015-2020)
6.2 Germany Familial Amyloid Polyneuropathy Revenue and Growth Rate (2015-2020)
6.3 UK Familial Amyloid Polyneuropathy Revenue and Growth Rate (2015-2020)
6.4 France Familial Amyloid Polyneuropathy Revenue and Growth Rate (2015-2020)
6.5 Russia Familial Amyloid Polyneuropathy Revenue and Growth Rate (2015-2020)
6.6 Italy Familial Amyloid Polyneuropathy Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Familial Amyloid Polyneuropathy Revenue by Countries
7.1 Asia-Pacific Familial Amyloid Polyneuropathy Revenue by Countries (2015-2020)
7.2 China Familial Amyloid Polyneuropathy Revenue and Growth Rate (2015-2020)
7.3 Japan Familial Amyloid Polyneuropathy Revenue and Growth Rate (2015-2020)
7.4 Korea Familial Amyloid Polyneuropathy Revenue and Growth Rate (2015-2020)
7.5 India Familial Amyloid Polyneuropathy Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Familial Amyloid Polyneuropathy Revenue and Growth Rate (2015-2020)
8 South America Familial Amyloid Polyneuropathy Revenue by Countries
8.1 South America Familial Amyloid Polyneuropathy Revenue by Countries (2015-2020)
8.2 Brazil Familial Amyloid Polyneuropathy Revenue and Growth Rate (2015-2020)
8.3 Argentina Familial Amyloid Polyneuropathy Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Familial Amyloid Polyneuropathy by Countries
9.1 Middle East & Africa Familial Amyloid Polyneuropathy Revenue by Countries (2015-2020)
9.2 Saudi Arabia Familial Amyloid Polyneuropathy Revenue and Growth Rate (2015-2020)
9.3 UAE Familial Amyloid Polyneuropathy Revenue and Growth Rate (2015-2020)
9.4 Egypt Familial Amyloid Polyneuropathy Revenue and Growth Rate (2015-2020)
9.5 South Africa Familial Amyloid Polyneuropathy Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Familial Amyloid Polyneuropathy Revenue and Market Share by Type (2015-2020)
10.2 Global Familial Amyloid Polyneuropathy Market Forecast by Type (2019-2024)
10.3 FAP-I Revenue Growth Rate (2015-2025)
10.4 FAP-II Revenue Growth Rate (2015-2025)
10.5 FAP-III Revenue Growth Rate (2015-2025)
10.6 FAP-IV Revenue Growth Rate (2015-2025)
11 Global Familial Amyloid Polyneuropathy Market Segment by Application
11.1 Global Familial Amyloid Polyneuropathy Revenue Market Share by Application (2015-2020)
11.2 Familial Amyloid Polyneuropathy Market Forecast by Application (2019-2024)
11.3 Hospitals and Clinics Revenue Growth (2015-2020)
11.4 Others Revenue Growth (2015-2020)
12 Global Familial Amyloid Polyneuropathy Market Size Forecast (2021-2025)
12.1 Global Familial Amyloid Polyneuropathy Market Size Forecast (2021-2025)
12.2 Global Familial Amyloid Polyneuropathy Market Forecast by Regions (2021-2025)
12.3 North America Familial Amyloid Polyneuropathy Revenue Market Forecast (2021-2025)
12.4 Europe Familial Amyloid Polyneuropathy Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Familial Amyloid Polyneuropathy Revenue Market Forecast (2021-2025)
12.6 South America Familial Amyloid Polyneuropathy Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Familial Amyloid Polyneuropathy Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US

List of Tables

Table 1. Global Familial Amyloid Polyneuropathy Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Familial Amyloid Polyneuropathy by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Familial Amyloid Polyneuropathy Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Familial Amyloid Polyneuropathy Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. Pfizer Corporate Information, Location and Competitors
Table 6. Pfizer Familial Amyloid Polyneuropathy Major Business
Table 7. Pfizer Familial Amyloid Polyneuropathy Total Revenue (USD Million) (2017-2018)
Table 8. Pfizer SWOT Analysis
Table 9. Pfizer Familial Amyloid Polyneuropathy Product and Solutions
Table 10. Pfizer Familial Amyloid Polyneuropathy Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 11. Alnylam Corporate Information, Location and Competitors
Table 12. Alnylam Familial Amyloid Polyneuropathy Major Business
Table 13. Alnylam Familial Amyloid Polyneuropathy Total Revenue (USD Million) (2018-2019)
Table 14. Alnylam SWOT Analysis
Table 15. Alnylam Familial Amyloid Polyneuropathy Product and Solutions
Table 16. Alnylam Familial Amyloid Polyneuropathy Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 17. GSK Corporate Information, Location and Competitors
Table 18. GSK Familial Amyloid Polyneuropathy Major Business
Table 19. GSK Familial Amyloid Polyneuropathy Total Revenue (USD Million) (2017-2018)
Table 20. GSK SWOT Analysis
Table 21. GSK Familial Amyloid Polyneuropathy Product and Solutions
Table 22. GSK Familial Amyloid Polyneuropathy Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 23. Arcturus Therapeutics Corporate Information, Location and Competitors
Table 24. Arcturus Therapeutics Familial Amyloid Polyneuropathy Major Business
Table 25. Arcturus Therapeutics Familial Amyloid Polyneuropathy Total Revenue (USD Million) (2017-2018)
Table 26. Arcturus Therapeutics SWOT Analysis
Table 27. Arcturus Therapeutics Familial Amyloid Polyneuropathy Product and Solutions
Table 28. Arcturus Therapeutics Familial Amyloid Polyneuropathy Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 29. Ionis Corporate Information, Location and Competitors
Table 30. Ionis Familial Amyloid Polyneuropathy Major Business
Table 31. Ionis Familial Amyloid Polyneuropathy Total Revenue (USD Million) (2017-2018)
Table 32. Ionis SWOT Analysis
Table 33. Ionis Familial Amyloid Polyneuropathy Product and Solutions
Table 34. Ionis Familial Amyloid Polyneuropathy Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 35. Proclara Bioscience Corporate Information, Location and Competitors
Table 36. Proclara Bioscience Familial Amyloid Polyneuropathy Major Business
Table 37. Proclara Bioscience Familial Amyloid Polyneuropathy Total Revenue (USD Million) (2017-2018)
Table 38. Proclara Bioscience SWOT Analysis
Table 39. Proclara Bioscience Familial Amyloid Polyneuropathy Product and Solutions
Table 40. Proclara Bioscience Familial Amyloid Polyneuropathy Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 41. Corino Therapeutics Corporate Information, Location and Competitors
Table 42. Corino Therapeutics Familial Amyloid Polyneuropathy Major Business
Table 43. Corino Therapeutics Familial Amyloid Polyneuropathy Total Revenue (USD Million) (2017-2018)
Table 44. Corino Therapeutics SWOT Analysis
Table 45. Corino Therapeutics Familial Amyloid Polyneuropathy Product and Solutions
Table 46. Corino Therapeutics Familial Amyloid Polyneuropathy Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 47. Global Familial Amyloid Polyneuropathy Revenue (Million USD) by Players (2015-2020)
Table 48. Global Familial Amyloid Polyneuropathy Revenue Share by Players (2015-2020)
Table 49. Global Familial Amyloid Polyneuropathy Revenue (Million USD) by Regions (2015-2020)
Table 50. Global Familial Amyloid Polyneuropathy Revenue Market Share by Regions (2015-2020)
Table 51. North America Familial Amyloid Polyneuropathy Revenue by Countries (2015-2020)
Table 52. North America Familial Amyloid Polyneuropathy Revenue Market Share by Countries (2015-2020)
Table 53. Europe Familial Amyloid Polyneuropathy Revenue (Million USD) by Countries (2015-2020)
Table 54. Asia-Pacific Familial Amyloid Polyneuropathy Revenue (Million USD) by Countries (2015-2020)
Table 55. South America Familial Amyloid Polyneuropathy Revenue by Countries (2015-2020)
Table 56. South America Familial Amyloid Polyneuropathy Revenue Market Share by Countries (2015-2020)
Table 57. Middle East and Africa Familial Amyloid Polyneuropathy Revenue (Million USD) by Countries (2015-2020)
Table 58. Middle East and Africa Familial Amyloid Polyneuropathy Revenue Market Share by Countries (2015-2020)
Table 59. Global Familial Amyloid Polyneuropathy Revenue (Million USD) by Type (2015-2020)
Table 60. Global Familial Amyloid Polyneuropathy Revenue Share by Type (2015-2020)
Table 61. Global Familial Amyloid Polyneuropathy Revenue Forecast by Type (2021-2025)
Table 62. Global Familial Amyloid Polyneuropathy Revenue by Application (2015-2020)
Table 63. Global Familial Amyloid Polyneuropathy Revenue Share by Application (2015-2020)
Table 64. Global Familial Amyloid Polyneuropathy Revenue Forecast by Application (2021-2025)
Table 65. Global Familial Amyloid Polyneuropathy Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Familial Amyloid Polyneuropathy Picture
Figure 2. Global Familial Amyloid Polyneuropathy Revenue Market Share by Type in 2019
Figure 3. FAP-I Picture
Figure 4. FAP-II Picture
Figure 5. FAP-III Picture
Figure 6. FAP-IV Picture
Figure 7. Familial Amyloid Polyneuropathy Revenue Market Share by Application in 2019
Figure 8. Hospitals and Clinics Picture
Figure 9. Others Picture
Figure 10. Global Familial Amyloid Polyneuropathy Revenue (USD Million) and Growth Rate (2015-2025)
Figure 11. North America Familial Amyloid Polyneuropathy Revenue (Million USD) and Growth Rate (2015-2025)
Figure 12. Europe Familial Amyloid Polyneuropathy Revenue (Million USD) and Growth Rate (2015-2025)
Figure 13. Asia-Pacific Familial Amyloid Polyneuropathy Revenue (Million USD) and Growth Rate (2015-2025)
Figure 14. South America Familial Amyloid Polyneuropathy Revenue (Million USD) and Growth Rate (2015-2025)
Figure 15. Middle East and Africa Familial Amyloid Polyneuropathy Revenue (Million USD) and Growth Rate (2015-2025)
Figure 16. Global Familial Amyloid Polyneuropathy Revenue (Million USD) and Growth Rate (2015-2025)
Figure 17. Global Familial Amyloid Polyneuropathy Revenue Share by Players in 2019
Figure 18. Global Top 5 Players Familial Amyloid Polyneuropathy Revenue Market Share in 2019
Figure 19. Global Top 10 Players Familial Amyloid Polyneuropathy Revenue Market Share in 2019
Figure 20. Key Players Market Share Trend
Figure 21. Global Familial Amyloid Polyneuropathy Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 22. Global Familial Amyloid Polyneuropathy Revenue Market Share by Regions (2015-2020)
Figure 23. Global Familial Amyloid Polyneuropathy Revenue Market Share by Regions in 2018
Figure 24. North America Familial Amyloid Polyneuropathy Revenue and Growth Rate (2015-2020)
Figure 25. Europe Familial Amyloid Polyneuropathy Revenue and Growth Rate (2015-2020)
Figure 26. Asia-Pacific Familial Amyloid Polyneuropathy Revenue and Growth Rate (2015-2020)
Figure 27. South America Familial Amyloid Polyneuropathy Revenue and Growth Rate (2015-2020)
Figure 28. Middle East and Africa Familial Amyloid Polyneuropathy Revenue and Growth Rate (2015-2020)
Figure 29. North America Familial Amyloid Polyneuropathy Revenue Market Share by Countries (2015-2020)
Figure 30. North America Familial Amyloid Polyneuropathy Revenue Market Share by Countries in 2019
Figure 31. USA Familial Amyloid Polyneuropathy Revenue and Growth Rate (2015-2020)
Figure 32. Canada Familial Amyloid Polyneuropathy Revenue and Growth Rate (2015-2020)
Figure 33. Mexico Familial Amyloid Polyneuropathy Revenue and Growth Rate (2015-2020)
Figure 34. Europe Familial Amyloid Polyneuropathy Revenue Market Share by Countries (2015-2020)
Figure 35. Europe Familial Amyloid Polyneuropathy Revenue Market Share by Countries in 2019
Figure 36. Germany Familial Amyloid Polyneuropathy Revenue and Growth Rate (2015-2020)
Figure 37. UK Familial Amyloid Polyneuropathy Revenue and Growth Rate (2015-2020)
Figure 38. France Familial Amyloid Polyneuropathy Revenue and Growth Rate (2015-2020)
Figure 39. Russia Familial Amyloid Polyneuropathy Revenue and Growth Rate (2015-2020)
Figure 40. Italy Familial Amyloid Polyneuropathy Revenue and Growth Rate (2015-2020)
Figure 41. Asia-Pacific Familial Amyloid Polyneuropathy Revenue Market Share by Countries (2015-2020)
Figure 42. Asia-Pacific Familial Amyloid Polyneuropathy Revenue Market Share by Countries in 2019
Figure 43. China Familial Amyloid Polyneuropathy Revenue and Growth Rate (2015-2020)
Figure 44. Japan Familial Amyloid Polyneuropathy Revenue and Growth Rate (2015-2020)
Figure 45. Korea Familial Amyloid Polyneuropathy Revenue and Growth Rate (2015-2020)
Figure 46. India Familial Amyloid Polyneuropathy Revenue and Growth Rate (2015-2020)
Figure 47. Southeast Asia Familial Amyloid Polyneuropathy Revenue and Growth Rate (2015-2020)
Figure 48. South America Familial Amyloid Polyneuropathy Revenue Market Share by Countries (2015-2020)
Figure 49. South America Familial Amyloid Polyneuropathy Revenue Market Share by Countries in 2019
Figure 50. Brazil Familial Amyloid Polyneuropathy Revenue and Growth Rate (2015-2020)
Figure 51. Argentina Familial Amyloid Polyneuropathy Revenue and Growth Rate (2015-2020)
Figure 52. Middle East and Africa Familial Amyloid Polyneuropathy Revenue Market Share by Countries (2015-2020)
Figure 53. Middle East and Africa Familial Amyloid Polyneuropathy Revenue Market Share by Countries in 2019
Figure 54. Saudi Arabia Familial Amyloid Polyneuropathy Revenue and Growth Rate (2015-2020)
Figure 55. UAE Familial Amyloid Polyneuropathy Revenue and Growth Rate (2015-2020)
Figure 56. Egypt Familial Amyloid Polyneuropathy Revenue and Growth Rate (2015-2020)
Figure 57. South Africa Familial Amyloid Polyneuropathy Revenue and Growth Rate (2015-2020)
Figure 58. Global Familial Amyloid Polyneuropathy Revenue Share by Type (2015-2020)
Figure 59. Global Familial Amyloid Polyneuropathy Revenue Share by Type in 2019
Figure 60. Global Familial Amyloid Polyneuropathy Market Share Forecast by Type (2021-2025)
Figure 61. Global FAP-I Revenue Growth Rate (2015-2020)
Figure 62. Global FAP-II Revenue Growth Rate (2015-2020)
Figure 63. Global FAP-III Revenue Growth Rate (2015-2020)
Figure 64. Global FAP-IV Revenue Growth Rate (2015-2020)
Figure 65. Global Familial Amyloid Polyneuropathy Revenue Share by Application (2015-2020)
Figure 66. Global Familial Amyloid Polyneuropathy Revenue Share by Application in 2019
Figure 67. Global Familial Amyloid Polyneuropathy Market Share Forecast by Application (2021-2025)
Figure 68. Global Hospitals and Clinics Revenue Growth Rate (2015-2020)
Figure 69. Global Others Revenue Growth Rate (2015-2020)
Figure 70. Global Familial Amyloid Polyneuropathy Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 71. Global Familial Amyloid Polyneuropathy Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 72. Global Familial Amyloid Polyneuropathy Revenue Market Share Forecast by Regions (2021-2025)
Figure 73. North America Familial Amyloid Polyneuropathy Revenue Market Forecast (2021-2025)
Figure 74. Europe Familial Amyloid Polyneuropathy Revenue Market Forecast (2021-2025)
Figure 75. Asia-Pacific Familial Amyloid Polyneuropathy Revenue Market Forecast (2021-2025)
Figure 76. South America Familial Amyloid Polyneuropathy Revenue Market Forecast (2021-2025)
Figure 77. Middle East and Africa Familial Amyloid Polyneuropathy Revenue Market Forecast (2021-2025)
Figure 78. Sales Channel: Direct Channel vs Indirect Channel

以下、関連資料のご紹介
  • 慢性炎症性脱髄性多発神経障害薬の世界市場レポート2020
    Global Chronic Inflammatory Demyelinating Polyneuropathy Drug Sales Market Report 2020
    20QY06-08491 2020年6月1日 134Pages
    QYResearch社の当調査資料では、慢性炎症性脱髄性多発神経障害薬のグローバル市場について種類別（GNbAC-1、GL-2045、ビオチン、その他）、用途別（病院、クリニック、その他）、地域別（北米、ヨーロッパ、中国、日本、東南アジア、インド）に区分して調査し、纏めました。2015年～2026年...
  • 胃食道逆流症（GERD）治療の世界市場 2020年：企業別、地域別、種類・用途別
    Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market 2020 by Company, Regions, Type and Application, Forecast to 2025
    D005-00431 2020年5月29日 108Pages
    本調査レポートでは、胃食道逆流症（GERD）治療の世界市場を広く調査・分析し、今後の市場展望をまとめております。胃食道逆流症（GERD）治療の種類別市場規模（制酸剤、運動促進剤、H2受容体遮断薬、プロトンポンプ阻害剤（PPI））、用途別市場規模（胸焼け、酸逆流症）、地域別市場規模（北米、アメリカ、ヨ...
  • 結核治療の世界市場 2020年：企業別、地域別、種類・用途別
    Global Tuberculosis Therapeutics Market 2020 by Company, Regions, Type and Application, Forecast to 2025
    D005-01035 2020年5月29日 100Pages
    本調査レポートでは、結核治療の世界市場を広く調査・分析し、今後の市場展望をまとめております。結核治療の種類別市場規模（イソニアジド、リファンピン、ピラジナミド、ヒドラジン誘導体、その他抗結核薬、エタンブトール）、用途別市場規模（外来手術センター、病院薬局、個人薬局）、地域別市場規模（北米、アメリカ、...
  • 脳卒中診断＆治療の世界市場 2020年：企業別、地域別、種類・用途別
    Global Stroke Diagnostics and Therapeutics Market 2020 by Company, Regions, Type and Application, Forecast to 2025
    D005-00952 2020年5月29日 100Pages
    本調査レポートでは、脳卒中診断＆治療の世界市場を広く調査・分析し、今後の市場展望をまとめております。脳卒中診断＆治療の種類別市場規模（診断、治療）、用途別市場規模（虚血性脳卒中、出血性脳卒中）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市...
  • ペット用がん治療の世界市場 2020年：メーカー別、地域別、種類・用途別
    Global Pet Cancer Therapeutics Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025
    D005-12013 2020年5月28日 102Pages
    本調査レポートでは、ペット用がん治療の世界市場を広く調査・分析し、今後の市場展望をまとめております。ペット用がん治療の種類別市場規模（化学療法、標的療法、併用療法、免疫療法）、用途別市場規模（リンパ腫、肥満細胞がん、黒色腫、乳腺、扁平上皮がん、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、ア...
  • リソソーム蓄積症治療の世界市場 2020年：企業別、地域別、種類・用途別
    Global Lysosomal Storage Diseases Therapeutics Market 2020 by Company, Regions, Type and Application, Forecast to 2025
    D005-00600 2020年5月29日 100Pages
    本調査レポートでは、リソソーム蓄積症治療の世界市場を広く調査・分析し、今後の市場展望をまとめております。リソソーム蓄積症治療の種類別市場規模（酵素補充療法、幹細胞療法、基質還元療法、その他）、用途別市場規模（病院、クリニック、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、...
  • 黒色腫治療の世界市場 2020年：企業別、地域別、種類・用途別
    Global Melanoma Therapeutics Market 2020 by Company, Regions, Type and Application, Forecast to 2025
    D005-00645 2020年5月29日 106Pages
    本調査レポートでは、黒色腫治療の世界市場を広く調査・分析し、今後の市場展望をまとめております。黒色腫治療の種類別市場規模（化学療法、免疫療法、標的療法、放射線療法）、用途別市場規模（オプジーボ、ヤーボイ、メカニスト + タフィンラー、キイトルーダ、コテル、ゼルボラフ、Imlygic、ジェネリック）、...
  • 移行上皮がん治療の世界市場 2020年：企業別、地域別、種類・用途別
    Global Transitional Cell Cancer Therapeutics Market 2020 by Company, Regions, Type and Application, Forecast to 2025
    D005-01028 2020年5月29日 105Pages
    本調査レポートでは、移行上皮がん治療の世界市場を広く調査・分析し、今後の市場展望をまとめております。移行上皮がん治療の種類別市場規模（膀胱腫瘍経尿道的切除、膀胱切除術、尿路変更術）、用途別市場規模（病院、がん研究所、多専門クリニック、外来手術センター）、地域別市場規模（北米、アメリカ、ヨーロッパ、ア...
  • 不眠症治療薬の世界市場 2020年：企業別、地域別、種類・用途別
    Global Insomnia Therapeutics Drugs Market 2020 by Company, Regions, Type and Application, Forecast to 2025
    D005-00534 2020年5月29日 101Pages
    本調査レポートでは、不眠症治療薬の世界市場を広く調査・分析し、今後の市場展望をまとめております。不眠症治療薬の種類別市場規模（ベンゾジアゼピン、非ベンゾジアゼピン、抗うつ薬、オレキシン拮抗薬、メラトニン拮抗薬、その他）、用途別市場規模（処方箋、店頭（OTC））、地域別市場規模（北米、アメリカ、ヨーロ...
  • リウマチ学治療薬の世界市場 2020年：企業別、地域別、種類・用途別
    Global Rheumatology therapeutics Market 2020 by Company, Regions, Type and Application, Forecast to 2025
    D005-00868 2020年5月29日 106Pages
    本調査レポートでは、リウマチ学治療薬の世界市場を広く調査・分析し、今後の市場展望をまとめております。リウマチ学治療薬の種類別市場規模（関節リウマチ、変形性関節症、ループス、痛風、強直性脊椎炎、その他）、用途別市場規模（小売薬局、オンライン薬局、病院）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジ...